Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small cell lung cancer ( NSCLC ) and high programmed death-ligand 1 ( PD-L1 ) expression ( tumor proportion score [ TPS ] greater than or equal to 50% ).
Researchers have compared the efficacy and safety of these treatments.
The efficacy and safety of the 1st line ICI-containing regimen between December 2017 and December 2019, were consecutively reviewed.
The patients were divided into the immune checkpoint inhibitor ( ICI ) with chemotherapy group ( the ICI-combo group ) and the ICI monotherapy group ( the ICI-mono group ).
Propensity score matching ( PSM ) was applied at a ratio of 1:1.
Of 450 advanced NSCLC patients who underwent 1st line treatment, 130 with PD-L1 TPS greater than or equal to 50% treated by an ICI-containing regimen.
Forty-eight were classified as the ICI-mono group, 30 into the ICI-combo group.
The median follow-up months was 6.0 months ( 0.5-11.9 ) in the ICI-combo group and 12.4 months ( 0.4-18.6 ) in the ICI-mono group.
The backgrounds of patients, age and performance status ( PS ) were almost similar.
An overall response rate ( ORR ) of the ICI-combo group was relatively higher than that of the ICI-mono group ( 76.9% vs. 55.8% ).
The median progression-free survival ( mPFS ) in the ICI-combo group was relatively longer in the ICI-mono group ( 10.5 months vs. 7.0 months; hazard ratio [ HR ], 0.44; 95% confidence interval [ CI ], 0.18 to 1.06 ).
This trend was also observed under PSM, HR 0.40 ( 95% CI, 0.13 to 1.19 ).
At the time of analysis, the median overall survival had not been reached.
Frequency of all adverse events and immune-related serious adverse events (irAE) of Grade 3 or higher were similar in both groups.
In conclusion, although overall survival result was immature, it was suggested that ICI-combo might have better short-term outcomes than ICI-mono. ( Xagena )
Source: European Society for Medical Oncology ( ESMO ) Virtual Meeting, 2020
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...